rifamycins
SusceptibilityIn Vitro Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, Including Macrolide- and Amikacin-Resistant Clinical IsolatesWe evaluated the in vitro activity of rifamycin derivatives, including rifampin, rifapentine, rifaximin, and rifabutin, against clinical nontuberculous mycobacteria (NTM) isolates. Of the rifamycin derivatives, rifabutin showed the lowest MICs against all NTM species, including Mycobacterium avium complex,...
SusceptibilityIn Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint InfectionThe in vitro activities of rifampin, rifabutin, rifapentine, and rifaximin were tested against 200 periprosthetic joint infection (PJI)-associated staphylococci. Seven rifampin-resistant isolates had MICs of ≥4 μg/ml. Three isolates had rifampin MICs of 0.25 to 1 μg/ml and harbored an Asp471Gly RpoB variant, suggesting that the CLSI rifampin-susceptible staphylococcal breakpoint of ≤1 μg/ml may be too high.
SusceptibilitySelect β-Lactam Combinations Exhibit Synergy against Mycobacterium abscessus In VitroMycobacterium abscessus is a nontuberculous mycobacterium that causes invasive pulmonary infections in patients with structural lung disease. M. abscessus is intrinsically resistant to several classes of antibiotics, and an increasing number of strains isolated from patients exhibit resistance to...
- Mechanisms of Action: Physiological EffectsBile Acids Improve the Antimicrobial Effect of Rifaximin
- Mechanisms of Action: Physiological EffectsPretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization Profiles
- Mechanisms of ResistanceRifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile
- Mechanisms of Action: Physiological EffectsIn Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus